Healthcare (R)evolution BIONICS - Future Is Becoming Reality March - - PowerPoint PPT Presentation
Knowledgeable Independent Focused Healthcare (R)evolution BIONICS - Future Is Becoming Reality March 22, 2018 ATONR PARTNERS SA 12, rue Pierre Fatio - 1204 GENEVA - SWITZERLAND - Tel: + 41 22 310 15 01 www.atonra.ch 2 Healthcare
ATONRÂ PARTNERS SA 12, rue Pierre Fatio - 1204 GENEVA - SWITZERLAND - Tel: + 41 22 310 15 01 www.atonra.ch
March 22, 2018
2
Source: AtonRâ Partners, WHO
Source: Grand View Research, Marketsandmarkets, Mordor Intelligence, Chief Observer, Infoholic
CAGR 2017-2023
45.2% 27.7% 18.3% 7.5% 9% 22%
5.6% 4.3%
3
4
5
This signal is transmitted to the brain’s somatosensory cortex
5
Translation into a neurophysiological signal Sensors generate an electrical signal Electrodes: ✓ detect the muscle contraction ✓ send electrical signals to the processor
Nerve endings remain Nerves rerouted to the muscle The patient wants to move his arm Nerves transmit signals to the muscle
The processor interprets the signal to provide the movement through motors Sensors detect texture,
pressure, and temperature
1 2 3 4 6 7 8 9 10
Amputee: The “Targeted Muscle Reinnervation” surgery:
6
The digital contact lens from Novartis and Google measure blood glucose levels from tears
Artificial pancreas wearable devices: Medtronic, Insulet, partnership between Dexcom, Tandem, and TypeZero The Zephyr BioPatch is a FDA-cleared small device monitoring the vital signs
7
INSULIN PUMP GLUCAGON PUMP ALGORITHM SENSOR
Blood Glucose Blood Glucose
1 2 3
8
9
Gecko toes are made up of hundreds of microscopic bristles
DNA-origami nanobots Bionic blood cells Robots that can climb or hang on various surfaces and work in extreme environments Waterproof adhesive bandage for Minimally Invasive Surgery (FDA approved) Nanoscopic machines that, once injected, roam through the body: ➢ Cancer treatment, drug & gene delivery, diagnostics & sensing devices
10
patient’s specific abilities
FDA clearance/approval:
▪ MindMotion Pro platform (MindMaze) ▪ SaeboVR rehab system (Saebo) ▪ VRPhysio (VR Health)
11
Pain management Schizophrenia, paranoia, anxiety… Medical and student training
Surgical visualization and planning
FDA clearance/approval:
▪ VRReliever (VR Health) ▪ Precision VR (Surgical
Theater)
▪ D2P Software Solution
(3D Systems)
Fight the fear of heights, spiders… 12
13
Human genes are put into bacteria in order to synthetize products ✓ Human Insulin, Growth Hormone, Vaccines etc. ✓ Rutinely used
Used to replace defective genes with healthy ones ✓ Against Tumors, AIDS, HIV, Genetic Disorders etc. ✓ One FDA approved therapy for a rare inherited eye disease (Spark Therapeutics)
Gene Therapy Medical Product Synthesis
14
T cells are genetically modified to recognize and kill patient’s specific cancer cells ✓ FDA approved for Acute Lymphoblastic Leukaemia (Novartis/Gilead Sciences) There are over 200 forms of cancer ✓ Personalization of treatment The protein Cas9, guided by a RNA-strand, acts like scissors and cuts a targeted gene(s) ✓ Introduction of new genes ✓ HIV, Zika, Malaria, Tumors etc. ✓ Human trials starting this year CRISPR/Cas9 System
Cas9 RNA-guide
15
CAR-T Cell Therapy Personalized medicine
01 17 02 17 03 17 04 17 05 17 06 17 07 17 08 17 09 17 10 17 11 17 12 17 01 18 02 18 03 18
An ageing world population A shortage of donated organs Major technology breakthroughs An improving outlook for reimbursements
16
As of 16 March, 2018
This report has been produced by the organizational unit responsible for investment research (Research unit) of AtonRâ Partners and sent to you by the company sales representatives. As an internationally active company, AtonRâ Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives
Although AtonRâ Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness
The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of AtonRâ Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such. Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate. It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns. Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing in any securities.
17